Viona Pharmaceuticals Recalls Metformin Due to NDMA
January 7, 2022
Updates to Fact Sheets for Johnson & Johnson COVID-19 Vaccine
January 11, 2022January 10, 2022 – Quviviq (daridorexant – Idorsia) has received FDA approval to treat adults who have insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
- Recommended dosing is 25mg to 50mg taken once nightly by mouth at least 30 minutes prior to going to bed, with at least seven hours remaining before the planned wake-up time. Taking the medication with or soon after a meal can delay time to sleep onset.
- The medication is currently awaiting U.S. Drug Enforcement Administration controlled substance scheduling, as it has the potential for abuse or dependence. The manufacturer anticipates launch in May 2022.